Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Cutaneous Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia
Contact: Study coordinator (Monica Osorio Clinical Trials Operations Manager) · Monica.Osorio@melanoma.org.au · +612 2 9911 7296

Study leads

Ines Da Silva
Principal Investigator
Melanoma Instiute Australia

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Towards Cure Via Only Ultra-short ICB in CSCC

Cutaneous Squamous Cell Carcinoma (CSCC) · Cutaneous Squamous Cell Cancer · Cutaneous Squamous Cell Carcinoma of the Head and Neck

Abroad (travel likely)RecruitingPHASE2

Maastricht, Netherlands · Amsterdam, Netherlands

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Solid Tumor · Advanced Cancer · Metastatic Cancer

Abroad (travel likely)RecruitingPHASE1

Tampa, United States · Durham, United States

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

Advanced Head and Neck Squamous Cell Carcinoma · Resectable Head and Neck Squamous Cell Carcinoma · Stage II Head and Neck Cutaneous Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Ann Arbor, United States

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Houston, United States